Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|June 1, 2007
Thrush
Author(s)Noah S. Scheinfeld, MD, JD
Oral candidiasis, or thrush, is not uncommon in elderly persons. It can be related to poor dentition or immunosuppression, particularly as a result of oral corticosteroid use.
Advertisement
Figure –
The white plaque on this patient's tongue can be easily removed to reveal underlying erythema. This finding is characteristic of thrush.
Oral Candidiasis
Oral candidiasis, or thrush, is not uncommon in elderly persons. It can be related to poor dentition or immunosuppression, particularly as a result of oral corticosteroid use. Thrush appears as white plaques that overlie areas of erythema on the buccal, palatal, or oropharyngeal mucosa (Figure). In most patients, the white film can be easily removed, which may reveal small ulcerations.
References:
FOR MORE INFORMATION:
- Brodell RT, Elewski B. Superficial fungal infections. Errors to avoid in diagnosis and treatment. Postgrad Med. 1997;101(4):279-287.
- Loo DS. Onychomycosis in the elderly: drug treatment options. Drugs Aging. 2007;24:293-302.
- Tan JS, Joseph WS. Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging. 2004;21;101-112.
- Weinberg JM, Scheinfeld NS. Cutaneous infections in the elderly: diagnosis and management. Dermatol Ther. 2003;16:195-205.
- Weinberg JM, Vafaie J, Scheinfeld NS. Skin infections in the elderly. Dermatol Clin. 2004;22:51-61.
Advertisement
Related to this article
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
Advertisement
Advertisement
Trending on Patient Care Online
1
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
Implementing Long-Acting HIV PrEP: Clinic and Pharmacy Infrastructure
4
3 Questions Primary Care Physicians Should Ask About Menopause Symptoms, With Stephanie Faubion, MD
5